Literature DB >> 21171894

Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma.

Joseph M Luettgen1, Robert M Knabb, Kan He, Donald J P Pinto, Alan R Rendina.   

Abstract

Apixaban is a potent, direct, selective, and orally active inhibitor of coagulation factor Xa. Rate constants for apixaban binding to free and prothrombinase-bound factor Xa were measured using multiple techniques. The inhibition mechanism was determined in purified systems and in a plasma prothrombin clotting time assay. Apixaban inhibits factor Xa with a K(i) of 0.25 nM at 37°C, an association rate constant of approximately 20 μM(-1) s(-1), and a dissociation half-life of 1-2 min. Under physiological conditions apixaban exhibits mixed-type inhibition and maintains high factor Xa affinity with a K(i) of 0.62 nM and association rate constant of 12 μM(-1) s(-1) for prothrombinase, and a K(i) of 1.7 nM and association rate constant of 4 μM(-1) s(-1) for the prothrombinase:prothrombin complex. Experiments in prothrombin depleted human plasma showed that the mechanism and kinetics of inhibition are maintained in plasma. The mechanistic detail derived from these experiments can be used to understand and interpret the pharmacodynamic action of apixaban.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21171894     DOI: 10.3109/14756366.2010.535793

Source DB:  PubMed          Journal:  J Enzyme Inhib Med Chem        ISSN: 1475-6366            Impact factor:   5.051


  13 in total

Review 1.  Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2012-06-18       Impact factor: 9.546

2.  Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor.

Authors:  Kan He; Joseph M Luettgen; Donglu Zhang; Bing He; James E Grace; Baomin Xin; Donald J P Pinto; Pancras C Wong; Robert M Knabb; Patrick Y S Lam; Ruth R Wexler; Scott J Grossman
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-04-02       Impact factor: 2.441

3.  Core shell stationary phase for a novel separation of some COVID-19 used drugs by UPLC-MS/MS Method: Study of grapefruit consumption impact on their pharmacokinetics in rats.

Authors:  Sally Tarek Mahmoud; Marwa A Moffid; Rawda M Sayed; Eman A Mostafa
Journal:  Microchem J       Date:  2022-07-15       Impact factor: 5.304

4.  Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.

Authors:  Charles Frost; Sunil Nepal; Jessie Wang; Alan Schuster; Wonkyung Byon; Rebecca A Boyd; Zhigang Yu; Andrew Shenker; Yu Chen Barrett; Rogelio Mosqueda-Garcia; Frank Lacreta
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

Review 5.  Apixaban: a review of its use for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

6.  [Pharmacology of the new oral anticoagulants].

Authors:  C-E Dempfle
Journal:  Herz       Date:  2012-06       Impact factor: 1.443

Review 7.  Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor.

Authors:  Pancras C Wong; Donald J P Pinto; Donglu Zhang
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

Review 8.  Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review.

Authors:  Wonkyung Byon; Samira Garonzik; Rebecca A Boyd; Charles E Frost
Journal:  Clin Pharmacokinet       Date:  2019-10       Impact factor: 6.447

9.  Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation.

Authors:  Genmin Lu; Joyce Lin; Khanh Bui; John T Curnutte; Pamela B Conley
Journal:  Res Pract Thromb Haemost       Date:  2020-08-27

10.  Apixaban Enhances Vasodilatation Mediated by Protease-Activated Receptor 2 in Isolated Rat Arteries.

Authors:  Ambra Villari; Giovanni Giurdanella; Claudio Bucolo; Filippo Drago; Salvatore Salomone
Journal:  Front Pharmacol       Date:  2017-07-18       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.